64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Major surgery within 12 weeks prior to enrollment into the study;

Brain metastasis;

Histologic diagnosis of small cell or neuroendocrine prostate cancer;

Prior history of leukemia or Myelodysplastic Syndrome;